SolAeroMed is the leader in biophysical
respiratory drugs.

Learn More

S-1226™

Cystic Fibrosis, Bronchiectasis, Asthma Rescue Drug & other chronic obstructive lung diseases including COVID-19
In Phase II Clinical Trials

S-1229™

Surfactant Dysfunction
In Pre-Clinical Development

 

[/one_third]

About SolAeroMed

SolAeroMed is a company dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases. Our lead drug, S-1226, is in Phase II clinical trials designed to demonstrate Proof of Concept.

Events

SolAeroMed is attending JP Morgan biotech conference in San Francisco Jan 13-18 2020.

Contact CEO Dr John Dennis to arrange a call or meeting: jdennis@solaeromedical.com




SolAeroMed is seeking development partners for their
novel Cystic Fibrosis, Asthma and Surfactant Dysfunction products.


Learn More


top